David D Ralph
Overview
Explore the profile of David D Ralph including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leary P, Rayner S, Branch K, Hogl L, Liston N, Barros L, et al.
Chest
. 2025 Jan;
PMID: 39761829
Background: Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in...
2.
Carlozzi L, Lee J, Barros L, Buber Y, Chen D, Mulligan M, et al.
Respir Med
. 2023 Mar;
211:107215.
PMID: 36934856
Introduction: Balloon pulmonary angioplasty (BPA) is a less invasive treatment alternative for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are unable to move forward with pulmonary thromboendarterectomy. This report...
3.
Pi H, Xia L, Ralph D, Rayner S, Shojaie A, Leary P, et al.
Circ Res
. 2023 Jan;
132(3):254-266.
PMID: 36597887
Background: Pulmonary arterial hypertension (PAH) is a complex disease characterized by progressive right ventricular (RV) failure leading to significant morbidity and mortality. Investigating metabolic features and pathways associated with RV...
4.
Hirsch K, Nolley S, Ralph D, Zheng Y, Altemeier W, Rhodes C, et al.
J Heart Lung Transplant
. 2022 Dec;
42(2):173-182.
PMID: 36470771
Background: Subtypes of pulmonary arterial hypertension (PAH) differ in both fundamental disease features and clinical outcomes. Angiogenesis and inflammation represent disease features that may differ across subtypes and are of...
5.
Pi H, Rayner S, Ralph D, Nolley S, Barros L, Steinberg Z, et al.
BMJ Open Respir Res
. 2022 Jul;
9(1).
PMID: 35879020
Introduction: Pulmonary arterial hypertension (PAH) remains a serious and life-threatening illness. Thyroid dysfunction is relatively understudied in individuals with PAH but is known to affect cardiac function and vascular tone...
6.
Pi H, Carlson S, Barros L, Hogl L, Kirkpatrick J, Nolley S, et al.
J Am Heart Assoc
. 2022 Jul;
11(14):e025521.
PMID: 35861845
No abstract available.
7.
Peplinski B, Houston B, Bluemke D, Kawut S, Kolb T, Kronmal R, et al.
J Card Fail
. 2021 Apr;
27(7):786-795.
PMID: 33872759
Background: Angiopoietin-1 and 2 (Ang1, Ang2) are important mediators of angiogenesis. Angiopoietin levels are perturbed in cardiovascular disease, but it is unclear whether angiopoietin signaling is causative, an adaptive response,...
8.
Lee J, Burger C, Delossantos G, Grinnan D, Ralph D, Rayner S, et al.
Ann Am Thorac Soc
. 2020 Jul;
17(12):1576-1582.
PMID: 32726561
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) typically undergo frequent clinical evaluation. The incidence and outcomes of coronavirus disease (COVID-19) and its impact on routine...
9.
Leary P, Jenny N, Bluemke D, Kawut S, Kronmal R, Lima J, et al.
J Heart Lung Transplant
. 2019 Sep;
39(1):45-52.
PMID: 31515065
Background: Circulating levels of endothelin-1 (ET1) are elevated in heart failure and predict poor prognosis. However, it is not clear whether ET1 elevation is an adaptive response, maladaptive response, or...
10.
H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program
Leary P, Hess E, Baron A, Branch K, Choudhary G, Hough C, et al.
Am J Respir Crit Care Med
. 2018 Feb;
197(12):1638-1641.
PMID: 29437490
No abstract available.